重症耐性肺結核患者に対するRifampicinの治療効果とくにRifampicin,Pyrazinamide併用療法について

概要

論文の詳細を見る
The therapeutic effects of Rifampicin 'RFP, on previously treated tuberculosis patients who failed to convert to negative in spite of long-term treatment with prim. and secondary drugs was analyzed. Fifty seven patients treated with RFP were divided into 3 groups. Group A: 18 cases in which RFP was given together with o ther sensitive drugs. Group B: 17 cases in which RFP was given together with pyrazinamide (PZA) (primary use) and isoniazide (resistant). Group C: 22 case s in which RFP was given together with other resistant drugs. RFP was given 450 mg daily before breakfast for 6 months to all patients and 450 mg twice a week for additional 6 months to the patients who attained negative conversion of bacilli within first 6 months treatment. The critical conce n tration for resistance to RFP were as follows: either the complete resistance to 10 mcg/ml of RFP or the incomplete resistance both to 10 mcg/ml and 50 mcg/ml. The results obtained were as follows: 1) Bacilli negative convertion rate wa s 77.8% in Group A, 50.0% in Group B and 36.4%in Group C after 3 months-treatment with RFP, and 88.9% in Group A, 57.1% in Group B and 36.4% in Group C after 6 months treatment. The combination of PZA with RFP seemed to be recomendable, when there was no other sensitive drugs. 2) The bacilli became resistant after 3 months treatm ent, if the bacilli failed to converted to negative. 3) The patients treated with RFP showed no serious side effect. In only one case, RFP was discontinued because of gastrointestinal disturbance, and S -GOT and S GPT values were elevated temporally in 3 cases.
一般社団法人日本結核病学会の論文

重症耐性肺結核患者に対するRifampicinの治療効果とくにRifampicin,Pyrazinamide併用療法について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク

重症耐性肺結核患者に対するRifampicinの治療効果 とくにRifampicin,Pyrazinamide併用療法について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク

重症耐性肺結核患者に対するRifampicinの治療効果とくにRifampicin,Pyrazinamide併用療法について